创新药板块景气度可持续，科创医药ETF嘉实(588700)近5日“吸金”超2000万元，规模创近1月新高

Group 1: ETF Performance - The liquidity of the Kexin Pharmaceutical ETF managed by Jiashi has a turnover rate of 24.54%, with a trading volume of 59.44 million yuan, indicating active market trading [2] - As of August 11, the Kexin Pharmaceutical ETF managed by Jiashi has reached a recent high in scale of 243 million yuan, ranking first among comparable funds [2] - The latest share count for the Kexin Pharmaceutical ETF managed by Jiashi is 205 million shares, also a recent high, and ranks first among comparable funds [2] Group 2: Fund Inflows and Returns - The Kexin Pharmaceutical ETF managed by Jiashi has seen a net inflow of 2.94 million yuan recently, with 4 out of the last 5 trading days showing net inflows totaling 20.52 million yuan [2] - As of August 11, the Kexin Pharmaceutical ETF managed by Jiashi has achieved a net value increase of 52.43% over the past year, ranking 584 out of 2954 in the index stock fund category, placing it in the top 19.77% [2] - Since its inception, the Kexin Pharmaceutical ETF managed by Jiashi has recorded a highest monthly return of 23.29%, with the longest consecutive monthly gains being 6 months and a maximum cumulative increase of 41.76% [2] Group 3: Top Holdings and Market Trends - As of July 31, the top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for a total of 49.14%, with leading companies including United Imaging Healthcare and BeiGene [2] - The innovative drug sector has maintained rapid growth in product revenue and external licensing over the past three years, with significant BD transactions this year driving the overall market trend [4] - The innovative drug sector is expected to sustain its growth due to ongoing policy support and increasing global competitiveness, while the medical device industry is anticipated to improve by 2025 [5]